Mitral insufficiency and ventricular remodeling: new alternatives for their control

Insuficiencia mitral y remodelación ventricular: nuevas alternativas para su control

The ventricular remodeling is a change in geometry and/or volume of the ventricular cavity non attributable to changes in the distension pressure, which produces a progressive increase in the time of the ventricular volume. Part of the mechanism responsible for it is the renal hypo perfusion, which produces an important loss in the glomerular filtration with the consequent activation of the system renina-angiotensin-aldosterone, which finally has an important contribution to the ventricular remodeling. At the present time, the use of ß-blockers and inhibitors of the angiotensin converting enzyme of (IECA) constitutes a good alternative to avoid the process of remodeling in patients with cardiac insufficiency, caused by a damage in the cardiac muscle (miocarditis), ischemic muscular damage (acute coronary disease) or by valvular injury (endocardiosis). As a result of the degeneration to valvular  myxomatous mitral (frequent in canine clinics), the patient develops cardiac insufficiency with left ventricular remodeling that in the long term ends up with the death of the animal. The use of ß-blockers or IECAS or their combination can avoid greatly their remodeling and thus avoid ventricular dysfunction from appearing.

1. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161-1172.
2. Guadalajara JF, Galván O, Noguera J, Alexanderson E, Cervantes JL, Huerta D. El mecanismo de remodelación en las sobrecargas de volumen del ventrículo izquierdo. Arch Inst Cardiol Méx.1995;65:217-228.
3. Beeri R, Yosefy C, Guerrero JL, Nesta F, Abedat S, Chaput M, del Monte F, et al. Mitral regurgitation augments post-myocardial infarction remodeling failure of hypertrophic compensation. J Am Coll Cardiol. 2008;51:476-486.
4. Passino C, Poletti R, Fontana M, Vergaro G, Prontera C, Gabutti A, Giannoni A, Emdin M, Clerico A. Clinical relevance of noncardiac determinants of natriuretic peptide levels. Clin Chem Lab Med. 2008;46:1515-1523.
5. De Simone R, Wolf I, Mottl-Link S, Hoda R, Mikhail B, Sack FU, Meinzer HP, Hagl S. A clinical study of annular geometry and dynamics in patients with ischemic mitral regurgitation: new insights into asymmetrical ring annuloplasty. Eur J Cardiothorac Surg. 2006;29:355-361.
6. Garrison JC. Histamine, Bradykinin, 5 hydroxytryptamine and their antagonist. En Goodman & Gilman`s. The pharmacological basis of therapeutics. Ed. Mc Graw Hill. 1991 pg. 749-63.
7. García D; Torruncha A. Los inhibidores de la enzima convertidora de angiotensina. Rev Cubana Cardiol Cir Cardiovasc. 1999;13:158-166.
8. Merril AJ, Morrison JL, Brannon ES. Concentration of renin in renal venous blood in patients with cronic heart failure. Am J Med. 1946;1:468-472.
9. Brown JJ, Davies DL, Johnson VW, Lever AF, Robertson JI. Renin relationships in congestive cardiac failure, treated and untreated. Am Heart J. 1970;80:329-342.
10. Agabiti-Rosei E, Muiesan ML. Influence of ACE inhibition on left ventricular hypertrophy. Br J Clin Pract. 1996;84 Suppl:17-22.
11. Kannel WB, D’Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D. Profile for estimating risk of heart failure. Arch Intern Med. 1999;159:1197-1204.
12. Shimamoto K, Kawana M. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial Nippon Rinsho. 2007;65 Suppl:531-536.
13. Perna E.R. Tratamiento de la disfunción ventricular sistólica asintomático. Rev Med Nord. 2003;4:1-4.
14. -----------------------------------------------------------------------------------
15. DOI: http://dx.doi.org/10.22490/24629448.400